Supernus Pharmaceuticals
Supernus Pharmaceuticals specializes in developing and marketing products for central nervous system (CNS) diseases, including epilepsy, migraine, Parkinson's disease, and ADHD, with a focus on innovation and support for healthcare providers and patients.
Services
Supernus Pharmaceuticals specializes in developing and commercializing products for the treatment of central nervous system (CNS) diseases. The company supports both patients and healthcare providers through its comprehensive resource center. This resource center offers a range of support and informational resources tailored to the needs of these two groups.
Products
Supernus Pharmaceuticals has a diverse portfolio of products targeting therapeutic categories such as CNS diseases. Their offerings include treatments for epilepsy, migraine, Parkinson's disease, and ADHD. This product portfolio reflects the company's commitment to addressing significant unmet medical needs within these areas.
Research and Development
Supernus Pharmaceuticals is actively engaged in research and development to create novel treatments for CNS conditions. The company has a pipeline of promising product candidates that are in various stages of clinical testing. This ongoing R&D effort is aimed at continually advancing the quality of care available for CNS disorders.
Company History
Supernus Pharmaceuticals has a history of innovation spanning over 30 years. Initially established as a stand-alone development organization, the company later operated as a U.S. subsidiary of Shire plc. In late 2005, it became Supernus Pharmaceuticals, Inc. This rich history highlights the company's longstanding dedication to improving CNS treatment options.
Grant Programs
Supernus Pharmaceuticals offers a variety of grants to medical, educational, and other organizations. These grants are part of the company's broader commitment to supporting the communities in which it operates and fostering advancements in medical education and research.